Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0778
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2620
    -0.0002 (-0.02%)
     
  • USD/JPY

    151.3640
    -0.0080 (-0.01%)
     
  • Bitcoin USD

    70,252.12
    +563.52 (+0.81%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,442.78
    +274.71 (+0.68%)
     

Portfolio Update

The Board notes the announcement made yesterday by Arecor Therapeutics plc ("Arecor"), one of the Company's investee companies, to seek to have its shares admitted to trading on AIM, RNS No: 6941Y.

Assuming the placing and admission takes place at a share price in the range indicated, the Company's value of its investment in Arecor is anticipated to increase. The Board intends to make a further announcement that will quantify that impact, after the admission has taken place.

For further information contact:

Oxford Technology Management

Lucius Cary

01865 784466


Advertisement